C-squared Pharma

Activities: Ingredients
C-squared Pharma

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Neuland Laboratories announces new $20m process development lab in Hyderabad The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of...
  2. Likarda and VitalTE LifeSciences join forces to simplify HRT with hydrogel drug delivery technology Core-Shell Spherification (CSS) aims to optimise the HRT process by promoting the extended and consistent release of hormones such as testosterone and oestrogen
  3. Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis...
  4. BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and...
  5. Single Use Support launches RoSS.BLST blast freezer with -80 °C recipe-driven protocols The 21 CFR Part 11 compliant platform offers 30% more chamber capacity within the same footprint, supporting up to 192 × 2L bottles per batch for consistent, scalable...

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

Related Content

Manufacturing
C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing
C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients
C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory
C2 Pharma's Tropicamide receives CEP from the European Directorate

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients
C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients
C2 Pharma to participate in DCAT Week 2024

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients
C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now